BMS Adds Nucleotide Analogue to its HCV Pipeline with US$2.5 B Inhibitex Acquisition

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 12 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1667     ISSN: 1756-7874

Section: Mergers & Acquisitions



Impressed by positive Phase Ib results of its hepatitis C virus (HCV) nucleotide polymerase inhibitor INX-189, Bristol-Myers Squibb (BMS) has agreed to purchase Inhibitex for US$26 per share in a deal that values the company at approximately US$$2...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details